ReviewStem cell research & therapy2026
Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent metabolic disorder that can progress from simple steatosis to chronic inflammation and fibrosis. Currently, pharmacological agents for MAFLD remain limited, and lifestyle-based management often fails to halt disease progression, underscoring the need for multitarget therapeutic strategies. Mesenchymal stem cells (MSCs) represent a promising regenerative and immunomodulatory therapy capable of reprogramming the hepatic inflammatory microenvironment, improving metabolic homeostasis, and limiting fibrogenesis. Increasing evidence indicates that MSC efficacy is largely mediated through paracrine mechanisms, with MSC-derived small extracellular vesicles (MSC-EVs) acting as key effectors by delivering functional cargos, including microRNAs (miRNAs) and proteins. MSC-EVs attenuate inflammation via inflammasome inhibition and macrophage polarization, restore insulin sensitivity and lipid handling through AMP-activated protein kinase (AMPK)-associated metabolic signaling, and also limit fibrogenesis by suppressing hepatic stellate cell (HSC) activation as part of their integrated multitarget actions. This review integrates current insights into MAFLD pathogenesis and the therapeutic mechanisms of MSCs and MSC-EVs, and highlights translational priorities for their clinical development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.